***Curriculum Vitae***

Dr. Shahla’a Fadhil Sabir

***Mustansiriyah University – The National Center of Hematology***

***Mobile****: +9647702688686*

***Email****:* [*shahlaa.fadhil@uomustansiriyah.edu.iq*](mailto:shahlaa.fadhil@uomustansiriyah.edu.iq)*;* [*shahlaa\_fadhil@yahoo.com*](mailto:shahlaa_fadhil@yahoo.com)

**Personal Summary:**

* Lecturer and researcher at the national center of hematology.

**Education:**

* Awarded Ph.D. degree in Medical Microbiology (Clinical Immunology), Medicine college/Baghdad University/2021
* Awarded M.Sc. degree in Microbiology (Clinical Immunology), Medicine college/Al-Mustinsiriya University/2013
* Awarded B.Sc. degree in Microbiology, Science College/Baghdad University/2002.

**ACADEMIC HONORS AND AWARDS:**

* #1:
* #2:

**ACADEMIC /TEACHING EXPERIENCE:**

* Teaching microbiology labs at Medicine college/Al-Mustinsiriya University for 1 day per a week for the 3rd class of under graduating medical students (2014, 2015, 2016, 2017 & 2022 class years).

**COURSES TAUGHT:**

|  |  |
| --- | --- |
| **Undergraduate** | **Graduate** |
| Medical microbiology |  |

**PROFESSIONAL AFFILIATIONS:**

* 2013-2016 Assistant Lecturer at the national center of hematology.
* 2016- till now Lecturer at the national center of hematology.
* 2015-2017 Chief of the quality assurance department and university performance at the national center of hematology.

**PUPLICATIONS:**

* Sabir SF, Alwatar WMA & Matti BF (2021). Impact of programmed death 1 expression in chronic myeloid leukemia at different molecular responses to imatinib mesylate treatment. Biochem. Cell. Arch., 21(1): 671-678.
* Sabir SF, Alwatar WMA & Matti BF (2021). Characteristic of CD4+CD25+ T cells in chronic myeloid leukemia patients treated with imatinib mesylate with different BCR-ABL transcripts levels response. Medico-legal Update, 21(1): 949-955.
* Matti BF, Sabir SF, Abdul Khaleq MA & Al Kaabi MH (2018). Serum calcium and phosphate levels in patients with chronic myeloid leukemia taking different dose of tyrosine kinase inhibitors. Al-Mustansiriyah Journal of Pharmaceutical Sciences (AJPS), 17(1): 213-221.
* Matti BF, Sabir SF, Abdul Khaleq MA & Al Kaabi MH (2017). Interleukin 1β level and c- reactive protein roles in primary myelofibrosis patients treated with hydroxyurea and ruxolitinib. Int. Res. J. Pharm., 8(6): 30-34.
* Sabir SF (2016). Assessment of interleukin-10 level and Janus kinase 2 V617F mutation incidence in patients with primary myelofibrosis. IraqiJ Hematol, 5(2):178-182.
* Abid -Alwadood S, Al-Shawk RS & Sabir SF (2016). The correlation of Lipocalin-2 and Retinol binding protein-4 with the inflammatory state in iraqi patients with T2DM. Iraqi Journal of Science, 2(57).
* Mohamed AH, Salman AF & Sabir SF (2015). Discrimination of types of hypochromic microcytic anemia using screening laboratory test. International journal of innovative and applied research, 3(2):8-11.
* Matti BF, Saleem MA & Sabir SF (2014). Assessment of Interleukin 1β serum level in different responder groups and stages of chronic myeloid leukemia patients on imatinb mesylate therapy. Indian J hematol blood transfuse, 30(4):247-252.
* Dhahi MAR, Matti BF & Sabir SF (2013). Molecular screening for T315I and F317L resistance mutayions in iraqi chronic myeloid leukemia non-responders patients to imatinib. cancer and clinical oncology journal, 2(2):55-61.
* AL-Kaabi MH, AL-Obaidy YG, Sabir SF & AL-Kadmy IM (2013). Incidence of JAK2 V617F mutation in Iraqi patients with Philadelphia positive CML. Mintage Journal of Pharmaceutical & Medical Sciences, 2(4):10-12.
* Matti BF, Naji AS, Majid AF, Sabir SF & Alwan AF (2013). Combination therapy of fludarabine and cyclophosphamide(FC) combination regmen in advance stage of chronic lymphocytic leukemia. Journal of the Faculty of Medicine Baghdad, 55(1):28-32.
* Sabir SF, Saleem MA & Matti BF (2013). Assessment of GM-CSF level in the serum of patients with different stages of chronic myeloid leukemia before and after imatinb mesylate therapy. Iraqi Journal of Hematology, 2(1):7-13.

**PROFFESSIONAL DEVELOPMENT**

* Conferences.
* Participated in 5th annual conference of the national center of hematology, 2015.
* Participated in 6th annual conference of Iraqi society of haematology & the national center of hematology, 2016.
* Participated in 7th annual conference of Iraqi society of haematology & the national center of hematology, 2017.
* Participated in 8th annual conference of the national center of hematology, 2018.
* Participated in 8th annual conference of Iraqi society of haematology, 2019.
* Participated in 9th annual conference of the national center of hematology, 2019.
* Participated in 9th annual virtual conference of Iraqi society of haematology, 2021.
* Participated in the international virtual conference of biotechnology research center, 2021.
* Workshops.
* Attended Research Management workshop, CRDF Global, 2013.
* Training in Applications of cytogenetics, Biotechnology research center, 2013.
* Attended Good clinical Practice workshop, 2014 .
* Attended Good clinical Practice workshop, 2015.
* Attended Biostatistics as applied to medical research workshop, 2015.

**الدكتورة شهلاء فاضل صابر**

***الجامعة المستنصرية – المركز الوطني لبحوث وعلاج امراض الدم***

***Mobile****: +9647702688686*

***Email****: :* [*shahlaa.fadhil@uomustansiriyah.edu.iq*](mailto:shahlaa.fadhil@uomustansiriyah.edu.iq)*;* [*shahlaa\_fadhil@yahoo.com*](mailto:shahlaa_fadhil@yahoo.com)

ملخص تعريفي:

* تدريسيية وباحثة في المركز الوطني لبحوث وعلاج امراض الدم.

**الشهادات الدراسية:**

* دكتوراه احياء مجهرية طبية (مناعة سريرية) / كلية الطب/ جامعة بغداد/2021
* ماجستير احياء مجهرية (مناعة سريرية) / كلية الطب/ الجامعة المستنصرية/2013
* بكلوريوس احياء مجهرية / كلية العلوم/ جامعة بغداد/2002

الجوائز والتكريم الأكاديمي

* #1:
* #2:

الخبرة الأكاديمية والتدريس:

* تدريس مختبر الأحياء المجهرية في كلية الطب/ الجامعة المستنصرية لمدة يوم واحد بالأسبوع للدراسات الأولية/ المرحلة الثالثة لسنوات الدراسية (2014,2015,2016,2017,2022).

**المقررات الدراسية التي تم تدريسها:**

|  |  |
| --- | --- |
| **الدراسات الأولية** | **الدراسات العليا** |
| الأحياء المجهرية الطبية |  |

**الأنتساب المهني او الجمعيات:**

* لجان
* رئيس ... الخ

**المنشورات العلمية**

* بحوث علمية.
* Sabir SF, Alwatar WMA & Matti BF (2021). Impact of programmed death 1 expression in chronic myeloid leukemia at different molecular responses to imatinib mesylate treatment. Biochem. Cell. Arch., 21(1): 671-678.
* Sabir SF, Alwatar WMA & Matti BF (2021). Characteristic of CD4+CD25+ T cells in chronic myeloid leukemia patients treated with imatinib mesylate with different BCR-ABL transcripts levels response. Medico-legal Update, 21(1): 949-955.
* Matti BF, Sabir SF, Abdul Khaleq MA & Al Kaabi MH (2018). Serum calcium and phosphate levels in patients with chronic myeloid leukemia taking different dose of tyrosine kinase inhibitors. Al-Mustansiriyah Journal of Pharmaceutical Sciences (AJPS), 17(1): 213-221.
* Matti BF, Sabir SF, Abdul Khaleq MA & Al Kaabi MH (2017). Interleukin 1β level and c- reactive protein roles in primary myelofibrosis patients treated with hydroxyurea and ruxolitinib. Int. Res. J. Pharm., 8(6): 30-34.
* Sabir SF (2016). Assessment of interleukin-10 level and Janus kinase 2 V617F mutation incidence in patients with primary myelofibrosis. IraqiJ Hematol, 5(2):178-182.
* Abid -Alwadood S, Al-Shawk RS & Sabir SF (2016). The correlation of Lipocalin-2 and Retinol binding protein-4 with the inflammatory state in iraqi patients with T2DM. Iraqi Journal of Science, 2(57).
* Mohamed AH, Salman AF & Sabir SF (2015). Discrimination of types of hypochromic microcytic anemia using screening laboratory test. International journal of innovative and applied research, 3(2):8-11.
* Matti BF, Saleem MA & Sabir SF (2014). Assessment of Interleukin 1β serum level in different responder groups and stages of chronic myeloid leukemia patients on imatinb mesylate therapy. Indian J hematol blood transfuse, 30(4):247-252.
* Dhahi MAR, Matti BF & Sabir SF (2013). Molecular screening for T315I and F317L resistance mutayions in iraqi chronic myeloid leukemia non-responders patients to imatinib. cancer and clinical oncology journal, 2(2):55-61.
* AL-Kaabi MH, AL-Obaidy YG, Sabir SF & AL-Kadmy IM (2013). Incidence of JAK2 V617F mutation in Iraqi patients with Philadelphia positive CML. Mintage Journal of Pharmaceutical & Medical Sciences, 2(4):10-12.
* Matti BF, Naji AS, Majid AF, Sabir SF & Alwan AF (2013). Combination therapy of fludarabine and cyclophosphamide(FC) combination regmen in advance stage of chronic lymphocytic leukemia. Journal of the Faculty of Medicine Baghdad, 55(1):28-32.
* Sabir SF, Saleem MA & Matti BF (2013). Assessment of GM-CSF level in the serum of patients with different stages of chronic myeloid leukemia before and after imatinb mesylate therapy. Iraqi Journal of Hematology, 2(1):7-13.

**تطوير المهارات:**

المؤتمرات:

* المشاركة بالمؤتمر السنوي الخامس للمركز الوطني لبحوث وعلاج امراض الدم, 2015.
* المشاركة بالمؤتمر السنوي السادس لجمعية امراض الدم العراقية والمركز الوطني لبحوث وعلاج امراض الدم, 2016.
* المشاركة بالمؤتمر السنوي السابع لجمعية امراض الدم العراقية والمركز الوطني لبحوث وعلاج امراض الدم, 2017.
* المشاركة بالمؤتمر السنوي الثامن للمركز الوطني لبحوث وعلاج امراض الدم, 2018.
* المشاركة بالمؤتمر السنوي الثامن لجمعية امراض الدم العراقية, 2019.
* المشاركة بالمؤتمر السنوي التاسع للمركز الوطني لبحوث وعلاج امراض الدم, 2019.
* المشاركة بالمؤتمر السنوي التاسع الأفتراضي لجمعية امراض الدم العراقية, 2021.
* المشاركة بالمؤتمر الأفتراضي لمركز بحوث التقنيات الأحيائية, 2021.

ورش العمل:

* • حضور ورشة عمل إدارة البحوث ، CRDF العالمية ، 2013.
* • تدريب في تطبيقات علم الوراثة الخلوية ، مركز أبحاث التكنولوجيا الحيوية ، 2013.
* • حضور ورشة عمل الممارسة السريرية الجيدة ، 2014.
* • حضور ورشة عمل الممارسة السريرية الجيدة ، 2015.
* • حضور ورشة عمل الإحصاء الحيوي المطبق على البحوث الطبية ، 2015.